buyers building, page-21

Another positive for vaccines...........

This is a example of a share breaking through resistance on good news. This is yesterdays chart so you'll have to project where the close was last night. nhamley prr's chart at the end of this, without yesterdays movement which was a very bullish close at 7.5 cents:)









Oncothyreon’s New Lung Cancer Data Hopeful (ONTY)
August 3, 2009 · Filed Under Cancer
Seattle-based Oncothyreon Inc. (Nasdaq: ONTY) is seeing new interest in its shares after the company demonstrated positive clinical data relating to long-term treatment with Stimuvax. The data were presented at the International Association for the Study of Lung Cancer’s 13th World Conference on Lung Cancer in San Francisco over this weekend.

The presentation was made by Dr. Glenwood Goss from the Ottawa Hospital Cancer Centre and it involved 16 patients who had received Stimuvax for between 2 and 8.2 years as part of the Phase 2b trial in patients with stage IIIb/IV non-small cell lung cancer.

As of the April 2009 date of the study data analysis, 10 of the 16 studied patients were alive without evidence of disease progression; and8 of those 10 continued to receive therapy with Stimuvax after 6.3 to 8.2 years. The remaining two living patients discontinued Stimuvax therapy after 2.4 and 5.8 years and were without evidence of disease progression. It also noted that 9 of the 10 living patients had stage IIIb NSCLC upon entry to the trial, while one had stage IV disease. Also noted was that 6 of the 10 living patients had a complete response to their first-line chemotherapy or chemo-radiation, while 4 patients had stable disease.

The remaining six of the 16 patients discontinued Stimuvax after 2.0 to 5.1 years of treatment as a result of disease progression and are deceased. The Phase 2b trial of Stimuvax in patients with stage IIIb/IV NSCLC was conducted by Oncothyreon, with patient enrollment concluding in 2003.

Long-term follow-up of these patients was conducted by Merck KGaA of Darmstadt, Germany, which assumed the clinical development of Stimuvax in 2007. Merck KGaA is responsible for the world-wide development and commercialization of Stimuvax under license from Oncothyreon and is currently conducting Phase 3 trials of Stimuvax in both NSCLC and breast cancer. Oncothyreon has already granted a license to Merck KGaA in Germany for the global development of Stimuvax®. Merck KGaA will be responsible worldwide for clinical development, manufacturing, including process development and scale-up for commercial manufacturing, and marketing.

Full data on the company’s weekend news is here on its website.

Interestingly enough, the company’s “Oncothyreon” is derived from the Greek words for tumor and shield. If you look ay the company’s pipeline, they also have treatments under Phase 1 for multiple solid tumors and a phase 2 for pancreatic cancer.

Shares are up 26% at $5.80 and we have seen already 1.7 million shares trade hands. It usually trades about 410,000 shares per day and its 52-week trading range is $0.62 to $6.25.

We do not have an updated balance sheet on this company, but the March 31 date showed about $15.7 million in cash and investments. Its market cap today is around $112 million.

Jon C. Ogg
August 3, 2009

Tags: ONTY